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Purpose. To evaluate whether introducing rapid diagnostic testing in conjunction with implementing a stratification algorithm for
testing eligibility would be an appropriate clinical and cost saving approach.Method. An internal concurrent 4-month observational
study was performed. Positive blood cultures continued to be worked up in accordance with standard of care. An additional
call to the infectious disease (ID) pharmacy service occurred for all positive blood cultures with Gram-positive cocci in clusters
(GPCC). The ID pharmacy service investigated each case using a prespecified stratification algorithm to minimize unnecessary
use of rapid identification testing. Results. 43 patients with GPCC were screened. Only nine patients met inclusion criteria for
QuickFISH testing. The average expected time avoided to optimize antibiotic therapy is 35 ± 16 hours. If the QuickFISH test
had been indiscriminately implemented for all cases, the cost for performing this test would have been $5,590. However, using the
prespecified algorithm, only 9 patients were tested for a projected cost of $1,170. Conclusion. Introducing rapid diagnostic testing in
conjunction with implementing patient stratification algorithm for rapid identification of GPCC from blood cultures in addition
to the ID pharmacy intervention will provide a positive impact on the clinical and economic outcomes in our health care setting.
1. Introduction
Coagulase-positive and coagulase-negative staphylococci
(CoNS) are commonly isolated from blood cultures. Staphy-
lococcus aureus (S. aureus) is responsible for a serious
bacteremia requiring immediate antibiotic treatment. Delay
in optimal therapy is associated with prolonged hospitaliza-
tion and higher rates of mortality [1]. Vancomycin initiation
is considered the standard of care for empiric therapy when
Gram-positive cocci in clusters (GPCC) are reported in
suspected blood stream infections. Furthermore, vancomycin
continues to be first line for the treatment of methi-
cillin-resistant Staphylococcus aureus (MRSA) bacteremia
with minimum inhibitory concentrations of ≤1.5mcg/mL.
However, this agent has been found to be inferior to
antistaphylococcal beta-lactams for methicillin-susceptible
Staphylococcus aureus (MSSA) strains [2, 3]. A previous
6-month retrospective chart review was performed at our
teaching hospital in an effort to characterize the most com-
mon Staph etiology. In this review, 16 cases were due toMSSA
and 26 were due to MRSA. The time to optimal coverage
for MSSA with an antistaphylococcal beta-lactam was 3.86
days. Patients with S. aureus bacteremia on average were
hospitalized for 12.3 days and received 29.7 days of antibiotic
therapy.
CoNS are common blood culture contaminants of which
only about 20% are considered true opportunistic pathogens
[4]. A typical contaminated blood culture investigation will
reveal only one positive culture out of multiple bottle draws,
no signs, or symptoms of endovascular infection and an
immunocompetent host. However, true CoNS bloodstream
infections are frequently associated with foreign bodies such
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as vascular catheters and implantable medical devices [5,
6]. Consequences of contaminated blood cultures include
increased cost, prolonged hospitalization, overuse of antibi-
otics with associated adverse events, and additional work for
members of the healthcare team [7]. A recent retrospective
review at our teaching hospital identified a positive blood
culture contamination rate of 35%.
Conventional methods of bacterial identification which
differentiate MRSA from MSSA and CoNS typically require
24–48 hours from the time blood cultures turn positive [8].
Rapid diagnostics are capable of identifying these organisms
in as little as 30 minutes from the positive blood culture
report [6]. Several studies have demonstrated the following:
a reduction in time to optimal antibiotic therapy by 1.7–2.5
days, a decrease in length of hospital stay by around 2–6 days,
and amedian reduction of hospital costs for up to $20,000 per
patient [5, 7, 9]. Previous studies have also identified that a
direct microbiology notification to an infectious disease (ID)
pharmacy team results in facilitation of this intervention [6].
Patients withmore than one infection pendingmicrobiologic
workup of other sites may require a continuation of empiric
vancomycin and would therefore not be expected to maxi-
mally benefit from rapid blood culture identification.
There are several molecular FDA approved methods for
rapid blood culture identification. Testing platforms include
GeneXpert, MALDI TOF mass spectrometry, and Quick-
FISH. Molecular methods range in testing sophistication,
need for equipment acquisition, and reagent cost. QuickFISH
GPCC BC (QF GPCC) is a peptide nucleic acid fluorescence
in situ hybridization (PNA-FISH) test capable of differen-
tiating staphylococci in positive blood cultures. QuickFISH
targets the 16S rRNA of S. aureus and CoNS directly from
positive blood cultures with a sensitivity and specificity
exceeding 98% [10, 11]. Fluorescently labeled probes bind to
a specified region of the bacterial RNA to form a distinct
green or red color when visualized under the microscope.
Organism identification is based on color emission.
Our teaching hospital uses culture based technology to
identify Staph species from positive blood cultures. The goal
of this study is to evaluatewhether introducing rapid diagnos-
tic testing in conjunction with implementing a stratification
algorithm for testing eligibility would be an appropriate
clinical and cost saving approach.
2. Methodology
An internal concurrent 4-month observational study was
performed. Due to platform availability at the time, Quick-
FISH was selected for this quality improvement project. For
the purpose of performing this validation study, test kits and
other equipment were provided by the manufacturer free of
charge. This study was approved by the Hospital Integrity
Board. During the study period, positive blood cultures
continued to beworked up in accordancewith the standard of
care. An additional call to the ID pharmacy service occurred
for all positive blood cultures with GPCC during the hours of
0700-1530.The ID pharmacy service investigated each case to
determine if rapid identification of the Staphylococcus species
would impact the use of antibiotics. If the ID pharmacy
service deemed there is a need to continue empiric van-
comycin, the rapid test would not be performed. However, if
the Staph bacteremia was considered to be a monomicrobic
infection or a potential contaminant and the patient was
on vancomycin, the blood culture isolate would be rapidly
identified.
The target population for testing was identified using a
stratified approach (Figure 1) and included age > 18 years,
immunocompetent, no foreign devices in place such as cen-
tral lines or cardiac devices, no additional infectious disease
indications requiring continuation of empiric vancomycin,
and no-risk factors for MRSA such as recent hospitalization,
recent antibiotic exposure, prior MRSA infection, or nasal
colonization. If the patient met criteria, the ID pharmacy
service would notifymicrobiology to run theQuickFISH test.
Results were notmade available for patient intervention since
the test results were used for research purposes only.
3. Definitions
We have defined optimal antibiotic therapy as the switch
from empiric vancomycin to cefazolin or nafcillin in patients
with MSSA bacteremia or discontinuation of unnecessary
vancomycin in patients with CoNS if deemed to be a contam-
inant. Time to optimal antibiotic therapy for culture based
methods was defined as the time microbiology reported the
GPCC after performing the Gram stain to the time of antibi-
otic optimization. For rapid diagnostic testing, the expected
time to optimal treatment for CoNS was defined as 2 hours
from the time when GPCC was identified by Gram stain
and 4 hours for S. aureus identification including mecA gene
determination. We calculated the expected time that could
have been avoided in hours to optimize antibiotic therapy
using the new technology by subtracting 2 hours (if CoNS)
or 4 hours (if MSSA) from the time to optimal antibiotic
therapy using culture basedmethodology formicrobiological
identification.
4. Results
A total of 43 patients with GPCC were screened for Quick-
FISH test eligibility. Nine patients met the inclusion criteria
for testing and therefore underwent QuickFISH (Table 1).
Time to optimal antibiotic therapy may be decreased by
approximately 20 to 74 hours (M = 35, SD = 16) for a
total of 314 hours. Among the nine patients, 7 patients had
CoNS and one hadmicrococcus. Among patients withCoNS,
call back to the emergency department (ED) would have
been avoided for 2 patients with contaminated bottles. One
patient with MSSA bacteremia would have been expected to
receive optimal therapy 74 hours earlier. A total of 34 patients
did not meet the criteria for QuickFISH testing (Table 2).
All the 34 patients received therapy with vancomycin for a
range of 3–14 days (median = 6 days). The majority of these
patients had CoNS (𝑁 = 28), 5 patients had MRSA, and 1
patient had MSSA. Of the 6 patients who were excluded due
to presence of MRSA risk factors, 4 cultures were deemed to
be contaminated and therefore we would have benefited from
knowing the identification rapidly to prevent unnecessary
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Positive blood culture with GPCC
Patient has additional ID indications necessitating continuation of 
empiric vancomycin
No
Immunocompromised or foreign device in place (e.g., central line) where 
coagulase-negative Staphylococcus may be an opportunistic pathogen warranting 
continuation of vancomycin
No
Perform rapid 
diagnostic testing
Yes
No need for rapid diagnostic 
testing
Yes
No need for rapid 
diagnostic testing
aGPCC = Gram-positive cocci in clusters
Figure 1: Criteria for rapid diagnostic testinga.
antibiotic exposure. Projected hospital cost avoidance in the
9 cases that met the inclusion criteria for testing if rapid
testing implemented is as follows: one patient with MSSA
bacteremia: using primary literature cost data by Bauer and
colleagues, the cost avoidance would have been $21,387; two
ED patients with contaminated blood culture bottles: cost
avoidance for ED call back would have been $718 × 2 =
$1436 (this cost represents the ED visit only and does not
include any interventions, doctors, pharmacists, and nurses
time, medications, imaging studies, cultures, or laboratory
tests); one patient had a contaminated blood culture bottle
and discharge held by one day with a cost avoidance for
extra day being approximately $1,024; and 5 patients for
which vancomycin was initiated due to the panic call of
GPCC in blood culture. The average drug acquisition cost
of vancomycin per day is approximately $20. Therefore, $100
in drug acquisition cost could have been avoided (this cost
does not include the cost for therapeutic drug monitoring
or additional case workup for positive blood culture inves-
tigation). If we apply Gander and colleagues’ estimates to all
8 contaminated blood cultures, the expected cost avoidance
would total (8 × $8,720) $69,760 [12]. During the study
period, 43 patients had GPCC reported in blood culture
bottles. Additionally, the projected cost for performing this
test is $130 per patient. This includes both the QuickFISH
and mecA gene tests as well as labor cost. If the QuickFISH
test had been indiscriminately implemented for all cases,
the cost for performing this test would have been $5,590.
However, using the stratified approach, only 9 patients were
tested for a projected cost of $1,170 and the cost avoidance
for untested patients, not including the 4 patients who
were inappropriately excluded because of MRSA risk factors,
would have been $3900.
5. Discussion
Time to optimal antibiotic therapy may be decreased by
approximately 1–3 days if interventions have been made
based on the results of the rapid diagnostic assays for the 9
cases that met the inclusion criteria for testing. Additionally,
earlier discharge may be achieved and call back to the ED
following discharge may be avoided. Stratification based on
eligibility for the rapid identification testminimizes the use of
this test for which early identification of GPCC is not likely to
impact empiric antibiotic therapy. Therefore, a stratification
algorithm for rapid molecular identification of GPCC from
blood cultures was created accordingly (Figure 1). Among the
34 patients who did not meet the criteria for rapid testing, 30
patients were appropriately excluded, while the cultures for
the remaining 4 patients were deemed to be contaminated
and therefore we would have benefited from knowing the
identification rapidly in order to prevent unnecessary antibi-
otic exposure. Therefore, we concluded that the presence of
MRSA risk factor does not appear to be appropriate exclusion
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Table 1: Patients who met inclusion criteria for rapid diagnostic testinga.
Age Gender Empiric therapy Isolatedmicroorganism Plan made
Time to optimal
antibiotic therapy
(hours) using
culture based
method
Expected time
avoided (hours) to
optimal antibiotic
therapy using the
molecular diagnostic
test
61 F Vancomycin MSSA Changed tonafcillin 78 74
68 M Vancomycin CoNS Vancomycindiscontinued 44 42
32 F Vancomycin andlevofloxacin CoNS
Discharged from
ED n/a 24
∗
78 F Vancomycin CoNS Vancomycindiscontinued 30 28
74 F Vancomycin anddoxycycline CoNS
Vancomycin
discontinued and
patient discharged
49 47
49 M Vancomycin CoNS Discharged fromED n/a 24
∗
80 F Vancomycin andceftriaxone Micrococcus
Vancomycin
discontinued 28 26
85 F Vancomycin andpiperacillin/tazobactam CoNS
Vancomycin
discontinued 22 20
29 M Vancomycin CoNS Vancomycindiscontinued 31 29
aF = female, M = male, MSSA = methicillin-susceptible Staphylococcus aureus, CoNS = coagulase-negative staphylococci, and ED = emergency department.
∗Patients were called to return for emergency department evaluation, to assess clinical status and repeat blood cultures.
Table 2: Patients who did not meet inclusion criteria for rapid
diagnostic testinga.
Reason for the exclusion Number ofpatients (𝑛 = 34)
Additional infectious disease indications
requiring continuation of empiric vancomycin 20
Immunocompromised host 3
Foreign device in place 5
Risk factor for MRSA 6
aMRSA = methicillin-resistant Staphylococcus aureus.
criteria and was consequently removed from the proposed
stratification algorithm.
Even thoughmolecular assays have been shown to reduce
the time to optimal antibiotic therapy as well as length of
hospital stay and cost of stay in previously published litera-
ture, in this observational study,we tested the appropriateness
of a stratified approach to minimize the use of the rapid
diagnostics to include only cases where early identification of
GPCC is likely to impact empiric antibiotic therapy.However,
this study has several limitations. First, it represented a small
sample size because the ID PharmD is not available 24
hours per day for 7 days to receive all the notifications for
GPCC. Second, it is a single center, 4-month observational
trial. Third, rapid diagnostic was tested for validation only
and the intervention was not allowed. Therefore, actual time
to optimal antibiotic therapy for rapid diagnostic test was
unable to be measured which could otherwise be longer
than 2 hours for CoNS and 4 hours for S. aureus. This time
included the expected microbiology workup time following
the Gram stain and did not include the lag time between
the microbiology reporting and the antibiotic optimization.
A two-arm, prospective study design could overcome this
limitation which is the potential future direction of this
trial. Fourth, the presence of MRSA risk factors was not an
appropriate exclusion criteria and was subsequently removed
from the hospital’s proposed rapid diagnostic stratifica-
tion algorithm. Finally, some of the cost avoidance data
were extrapolated from previously published cost avoidance
trials.
6. Conclusion
Introducing rapid molecular testing in conjunction with
implementing patient stratification algorithm for rapid
molecular identification of GPCC from blood cultures in
addition to the ID pharmacy intervention will provide a
positive impact on the clinical and economic outcomes in our
health care setting.
Disclosure
Thamer A. Almangour is a Former PGY2 Infectious Diseases
Pharmacy Resident at Columbus Regional Health, Midtown
Medical Center. Abdullah A. Alhifany is a Former PGY1
Canadian Journal of Infectious Diseases and Medical Microbiology 5
Pharmacy Practice Resident at Columbus Regional Health,
Midtown Medical Center.
Conflicts of Interest
QuickFISH test kits and equipment were provided by the
manufacturer free of charge for the purpose of performing
this validation study (Thamer A. Almangour). The authors
declare that there are no additional conflicts of interest
regarding the publication of this paper.
References
[1] T. P. Lodise, P. S. McKinnon, L. Swiderski, and M. J. Rybak,
“Outcomes analysis of delayed antibiotic treatment for hospital-
acquired Staphylococcus aureus bacteremia,” Clinical Infectious
Diseases, vol. 36, no. 11, pp. 1418–1423, 2003.
[2] S. H. Kim, K. H. Kim,H. B. Kim et al., “Outcome of vancomycin
treatment in patient with methicillin-susceptible staphylococ-
cus aureus bacteremia,” Antimicrobial Agents and Chemother-
apy, vol. 52, pp. 192–197, 2008.
[3] F.-Y. Chang, J. E. Peacock Jr., D. M.Musher et al., “Staphylococ-
cus aureus bacteremia: recurrence and the impact of antibiotic
treatment in a prospective multicenter study,”Medicine, vol. 82,
no. 5, pp. 333–339, 2003.
[4] S. E. Beekmann, D. J. Diekema, and G. V. Doern, “Determining
the clinical significance of coagulase-negative staphylococci
isolated from blood cultures,” Infection Control and Hospital
Epidemiology, vol. 26, no. 6, pp. 559–566, 2005.
[5] T. Ly, J. Gulia, V. Pyrgos, M. Waga, and S. Shoham, “Impact
upon clinical outcomes of translation of PNA FISH-generated
laboratory data from the clinicalmicrobiology bench to bedside
in real time,”Therapeutics and Clinical Risk Management, vol. 4,
no. 3, pp. 637–640, 2008.
[6] J. R. Wong, K. A. Bauer, J. E. Mangino, and D. A. Goff, “Antimi-
crobial stewardship pharmacist interventions for coagulase-
negative staphylococci positive blood cultures using rapid
polymerase chain reaction,”Annals of Pharmacotherapy, vol. 46,
no. 11, pp. 1484–1490, 2012.
[7] G. N. Forrest, S. Mehta, E. Weekes, D. P. Lincalis, J. K. Johnson,
and R. A. Venezia, “Impact of rapid in situ hybridization testing
on coagulase-negative staphylococci positive blood cultures,”
Journal of Antimicrobial Chemotherapy, vol. 58, no. 1, pp. 154–
158, 2006.
[8] A. M. Frye, C. A. Baker, D. L. Rustvold et al., “Clinical impact of
a real-time PCR assay for rapid identification of staphylococcal
bacteremia,” Journal of Clinical Microbiology, vol. 50, no. 1, pp.
127–133, 2012.
[9] K. A. Bauer, J. E. West, J.-M. Balada-Llasat, P. Pancholi, K.
B. Stevenson, and D. A. Goff, “An antimicrobial stewardship
program’s impact with rapid polymerase chain reaction meth-
icillin-resistant Staphylococcus aureus/S. aureus blood culture
test in patients with S. aureus bacteremia,” Clinical Infectious
Diseases, vol. 51, no. 9, pp. 1074–1080, 2010.
[10] K.Oliveira, S.M. Brecher, A.Durbin et al., “Direct identification
of Staphylococcus aureus from positive blood culture bottles,”
Journal of ClinicalMicrobiology, vol. 41, no. 2, pp. 889–891, 2003.
[11] K. Oliveira, G. W. Procop, D. Wilson, J. Coull, and H. Stender,
“Rapid identification of staphylococcus aureus directly from
blood cultures by fluorescence in situ hybridization with pep-
tide nucleic acid probes,” Journal of Clinical Microbiology, vol.
40, no. 1, pp. 247–251, 2002.
[12] R. M. Gander, L. Byrd, M. DeCrescenzo, S. Hirany, M. Bowen,
and J. Baughman, “Impact of blood cultures drawn by phle-
botomy on contamination rates and health care costs in a hos-
pital emergency department,” Journal of Clinical Microbiology,
vol. 47, no. 4, pp. 1021–1024, 2009.
